Compare Stocks: GLMD, ACTU, LPCN, and CLRB

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ACTU Actuate Therapeutics	$0.81 -7.3%	$1.11	$0.60 ▼ $8.49	$19.67M	1.2	212,493 shs	92,584 shs
CLRB Cellectar Biosciences	$1.60 -4.5%	$2.37	$1.57 ▼ $5.59	$15.08M	0.58	384,475 shs	78,810 shs
GLMD Galmed Pharmaceuticals	$4.59 -0.9%	$4.45	$3.29 ▼ $13.20	$4.78M	0.67	52,894 shs	302,067 shs
LPCN Lipocine	$2.07 -0.2%	$2.17	$1.81 ▼ $12.37	$17.02M	0.4	184,320 shs	9,300 shs

The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout

The AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ACTU Actuate Therapeutics	+6.83%	+18.84%	-40.89%	-42.44%	-87.47%
CLRB Cellectar Biosciences	-6.18%	-8.74%	-29.54%	-38.15%	-71.11%
GLMD Galmed Pharmaceuticals	0.00%	0.00%	+18.30%	+0.83%	-63.46%
LPCN Lipocine	+0.98%	-0.96%	-15.51%	-16.19%	-38.21%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ACTU Actuate Therapeutics	$0.81 -7.3%	$1.11	$0.60 ▼ $8.49	$19.67M	1.2	212,493 shs	92,584 shs
CLRB Cellectar Biosciences	$1.60 -4.5%	$2.37	$1.57 ▼ $5.59	$15.08M	0.58	384,475 shs	78,810 shs
GLMD Galmed Pharmaceuticals	$4.59 -0.9%	$4.45	$3.29 ▼ $13.20	$4.78M	0.67	52,894 shs	302,067 shs
LPCN Lipocine	$2.07 -0.2%	$2.17	$1.81 ▼ $12.37	$17.02M	0.4	184,320 shs	9,300 shs

The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ACTU Actuate Therapeutics	+6.83%	+18.84%	-40.89%	-42.44%	-87.47%
CLRB Cellectar Biosciences	-6.18%	-8.74%	-29.54%	-38.15%	-71.11%
GLMD Galmed Pharmaceuticals	0.00%	0.00%	+18.30%	+0.83%	-63.46%
LPCN Lipocine	+0.98%	-0.96%	-15.51%	-16.19%	-38.21%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ACTU Actuate Therapeutics	2.33	Hold	$10.50	1,194.70% Upside
CLRB Cellectar Biosciences	2.80	Moderate Buy	$11.00	589.66% Upside
GLMD Galmed Pharmaceuticals	1.00	Sell	N/A	N/A
LPCN Lipocine	2.00	Hold	$4.00	93.61% Upside

Current Analyst Ratings Breakdown

Latest GLMD, ACTU, LPCN, and CLRB Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/24/2026	LPCN Lipocine	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
9/22/2026	LPCN Lipocine	Cantor Fitzgerald Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Overweight
9/21/2026	ACTU Actuate Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
9/21/2026	LPCN Lipocine	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Neutral	$4.00
9/3/2026	LPCN Lipocine	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
8/19/2026	LPCN Lipocine	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
8/18/2026	ACTU Actuate Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
7/30/2026	ACTU Actuate Therapeutics	Rodman & Renshaw Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$6.00
7/17/2026	CLRB Cellectar Biosciences	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
7/17/2026	GLMD Galmed Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
7/12/2026	CLRB Cellectar Biosciences	Brookline Capital Markets Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong-Buy

(Data available from 10/6/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ACTU Actuate Therapeutics	N/A	N/A	N/A	N/A	$0.34 per share	N/A
CLRB Cellectar Biosciences	N/A	N/A	N/A	N/A	$1.89 per share	N/A
GLMD Galmed Pharmaceuticals	N/A	N/A	N/A	N/A	$23.04 per share	N/A
LPCN Lipocine	$1.98M	8.60	N/A	N/A	$2.61 per share	0.79

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ACTU Actuate Therapeutics	-$22.23M	-$0.87	N/A	N/A	N/A	N/A	-346.19%	-178.40%	N/A
CLRB Cellectar Biosciences	-$21.79M	-$3.84	N/A	N/A	N/A	N/A	-185.35%	-115.42%	10/29/2026 (Estimated)
GLMD Galmed Pharmaceuticals	-$10.31M	-$15.18	N/A	N/A	N/A	N/A	-73.68%	-60.88%	11/25/2026 (Estimated)
LPCN Lipocine	-$9.63M	-$1.79	N/A	N/A	N/A	-755.39%	-64.75%	-57.62%	11/5/2026 (Estimated)

Latest GLMD, ACTU, LPCN, and CLRB Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
9/2/2026	Q2 2026	GLMD Galmed Pharmaceuticals	-$3.12	-$2.86	+$0.26	-$2.86	N/A	N/A
8/14/2026	Q2 2026	ACTU Actuate Therapeutics	-$0.21	-$0.20	+$0.01	-$0.20	N/A	N/A
8/13/2026	Q2 2026	CLRB Cellectar Biosciences	-$0.52	-$0.57	-$0.05	-$0.57	$12.00 million	N/A
8/4/2026	Q2 2026	LPCN Lipocine	-$0.40	-$0.32	+$0.08	-$0.32	$0.21 million	$0.19 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ACTU Actuate Therapeutics	N/A	N/A	N/A	N/A	N/A
CLRB Cellectar Biosciences	N/A	N/A	N/A	N/A	N/A
GLMD Galmed Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
LPCN Lipocine	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ACTU Actuate Therapeutics	N/A	1.25	1.25
CLRB Cellectar Biosciences	N/A	6.66	6.66
GLMD Galmed Pharmaceuticals	N/A	4.16	4.16
LPCN Lipocine	N/A	11.48	11.48

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ACTU Actuate Therapeutics	N/A
CLRB Cellectar Biosciences	16.41%
GLMD Galmed Pharmaceuticals	76.14%
LPCN Lipocine	9.11%

Insider Ownership

Company	Insider Ownership
ACTU Actuate Therapeutics	57.98%
CLRB Cellectar Biosciences	2.58%
GLMD Galmed Pharmaceuticals	19.80%
LPCN Lipocine	4.69%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ACTU Actuate Therapeutics	12	24.01 million	10.09 million	N/A
CLRB Cellectar Biosciences	11	9.45 million	9.21 million	No Data
GLMD Galmed Pharmaceuticals	20	1.04 million	836,000	Not Optionable
LPCN Lipocine	14	8.24 million	7.86 million	No Data

GLMD, ACTU, LPCN, and CLRB Headlines

Recent News About These Companies

Lipocine (NASDAQ:LPCN) Stock: Insider John Higuchi Purchases 15,970 Shares

October 3 at 4:52 AM | americanbankingnews.com

Lipocine (NASDAQ:LPCN) Stock: Insider John Higuchi Buys 9,037 Shares

October 3 at 4:52 AM | americanbankingnews.com

Lipocine consensus price target decreased by 16.67% to $5.10

October 2, 2026 | msn.com

Lipocine (NASDAQ:LPCN) Director Purchases 9,037 Shares of Stock

October 2, 2026 | insidertrades.com

Lipocine (NASDAQ:LPCN) Stock: Insider John Higuchi Buys 12,561 Shares

October 2, 2026 | americanbankingnews.com

Lipocine (NASDAQ:LPCN) Director Purchases $27,131.76 in Stock

October 1, 2026 | insidertrades.com

HC Wainwright Has Bullish Forecast for Lipocine Q3 Earnings

September 25, 2026 | americanbankingnews.com

Lipocine (LPCN) Upgraded to Buy: What Does It Mean for the Stock?

September 23, 2026 | zacks.com

Lipocine Announces Initiation of BLOOM Phase 3 Study of LPCN 1154 for Postpartum Depression

September 14, 2026 | prnewswire.com

Lipocine Updates Sales Agreement Fee Structure with A.G.P.

September 11, 2026 | tipranks.com

Lipocine to Present at the H.C. Wainwright 28th Annual Global Investment Conference

September 10, 2026 | prnewswire.com

Lipocine to Present at H.C. Wainwright Investment Conference

September 10, 2026 | tipranks.com

Lipocine Announces Financial Results for the Second Quarter Ended June 30, 2026

August 4, 2026 | prnewswire.com

Lipocine Appoints Industry Veteran Grissinger to Board

August 3, 2026 | tipranks.com

Lipocine Inc. to Host Virtual KOL Event Highlighting Unmet Needs in Postpartum Depression and the Clinical Profile of LPCN 1154

June 4, 2026 | prnewswire.com

Lipocine Announces LPCN 1154 Phase 3 Data Accepted for Oral Presentation at 2026 ASCP Annual Meeting

May 19, 2026 | prnewswire.com

Anaveon Strengthens Leadership Team with Appointments of Eric Zanelli as Chief Scientific Officer and Jill Jene as Chief Business Officer

May 19, 2026 | globenewswire.com

Lipocine to Present at A.G.P.'s Annual Virtual Healthcare Company Showcase

May 18, 2026 | prnewswire.com

Lipocine Inc.: Lipocine Announces Financial Results for the First Quarter Ended March 31, 2026

May 9, 2026 | finanznachrichten.de

Lipocine (LPCN) Reports Q1 Loss, Beats Revenue Estimates

May 7, 2026 | zacks.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

GLMD, ACTU, LPCN, and CLRB Company Descriptions

Actuate Therapeutics NASDAQ:ACTU

$0.81 -0.06 (-7.30%)

As of 01:58 PM Eastern

Actuate Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for the treatment of cancers. The company's lead product candidate is Elraglusib Injection, a novel glycogen synthase kinase-3 inhibitor to treat metastatic pancreatic ductal adenocarcinoma. It also develops Elraglusib for the treatment of Ewing sarcoma, metastatic melanoma, and colorectal cancer. The company was formerly known as Apotheca Therapeutics, Inc. and changed its name to Actuate Therapeutics, Inc. in October 2015. The company was incorporated in 2015 and is based in Fort Worth, Texas.

Cellectar Biosciences NASDAQ:CLRB

$1.60 -0.08 (-4.49%)

As of 01:59 PM Eastern

Cellectar Biosciences, Inc., a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer. Its lead phospholipid drug conjugate (PDC) candidate is CLR 131 (iopofosine I-131), which is in Phase 2 clinical study for patients with B-cell malignancies; Phase 2a clinical study for patients with relapsed or refractory (r/r) Waldenstrom's macroglobulinemia cohort, r/r multiple myeloma (MM) cohort, and r/r non-Hodgkin's lymphoma cohort; Phase 1 clinical study for r/r pediatric patients with select solid tumors, lymphomas, and malignant brain tumors; and Phase 1 clinical study for r/r head and neck cancer. The company also develops CLR 1900, a PDC chemotherapeutic program that is in the preclinical development stage to treat solid tumors. It has collaborative with Orano Med to develop CLR 12120 Series; and LegoChemBio. The company was founded in 2002 and is headquartered in Florham Park, New Jersey.

Galmed Pharmaceuticals NASDAQ:GLMD

$4.59 -0.04 (-0.86%)

Closing price 09/9/2026

Extended Trading

$4.59 0.00 (0.00%)

As of 09/9/2026 07:56 PM Eastern

Galmed Pharmaceuticals Ltd., a biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. It develops Aramchol, an oral therapy, which is in Phase III study for the treatment of non-alcoholic steato-hepatitis (NASH) in patients with overweight or obesity and who are pre-diabetic or type-II-diabetes mellitus. The company also evaluates Aramchol through ARRIVE Study, a Phase IIa clinical trial with HIV-associated non-alcoholic fatty liver disease and lipodystrophy. In addition, it engages in the development of Amilo-5MER, a 5 amino acid synthetic peptide methionine, threonine, alanine, aspartic acid, and valine. It has a license agreement with Samil Pharma. Co., Ltd. for the commercialization of Aramchol in the Republic of Korea; and a collaboration agreement with OnKai for its AI platform. Galmed Pharmaceuticals Ltd. was founded in 2000 and is headquartered in Tel Aviv, Israel.

Lipocine NASDAQ:LPCN

$2.07 0.00 (-0.19%)

As of 01:52 PM Eastern

Lipocine Inc., a clinical-stage biopharmaceutical company, engages in the research and development for the delivery of drugs for the treatment of central nervous system (CNS) disorders. Its lead product candidate is TLANDO, an oral testosterone replacement therapy (TRT) comprising testosterone undecanoate. The company's pipeline candidates also include TLANDO XR a candidate for oral TRT for once daily dosing, which has completed Phase 2b clinical study; LPCN 1148, an oral prodrug of bioidentical testosterone, being developed for the treatment of cirrhosis, currently under Phase 2 clinical studies; LPCN 1154, An oral neurosteroid, being developed for the treatment of postpartum depression, currently under Phase 2 studies; LPCN 2101, a NAS candidate, for women with epilepsy; and LPCN 2203 for essential tremor. It is also involved in the development of LPCN 1144, an oral prodrug of bioidentical testosterone for the treatment of pre-cirrhotic non-alcoholic steatohepatitis, which has completed Phase 2 testing; and LPCN 1107, an oral product candidate of 17-alpha-hydroxy progesterone caproate product, currently under Phase 3 studies for the prevention of recurrent preterm birth. The company was founded in 1997 and is headquartered in Salt Lake City, Utah.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest GLMD, ACTU, LPCN, and CLRB Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest GLMD, ACTU, LPCN, and CLRB Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

GLMD, ACTU, LPCN, and CLRB Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

GLMD, ACTU, LPCN, and CLRB Company Descriptions

Actuate Therapeutics NASDAQ:ACTU

Cellectar Biosciences NASDAQ:CLRB

Galmed Pharmaceuticals NASDAQ:GLMD

Lipocine NASDAQ:LPCN

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest GLMD, ACTU, LPCN, and CLRB Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest GLMD, ACTU, LPCN, and CLRB Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

GLMD, ACTU, LPCN, and CLRB Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

GLMD, ACTU, LPCN, and CLRB Company Descriptions

Actuate Therapeutics NASDAQ:ACTU

Cellectar Biosciences NASDAQ:CLRB

Galmed Pharmaceuticals NASDAQ:GLMD

Lipocine NASDAQ:LPCN

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools